Fibroblasts in the tumour stroma, called cancer-associated fibroblasts (CAFs), have been reported to induce chemotherapeutic resistance in lung cancer. Actually, a large number of studies showed that CAFs promoted the metastatic ability, invasion and proliferation of lung cancer cells, which induce resistance to chemotherapy by secreting a number of growth factors and inflammatory chemokines. 4, 5 Furthermore, a part of CAFs has myofibroblast (MF) characteristic with the expression of alpha-smooth muscle actin (α-SMA), which substantially promotes chemotherapeutic resistance by expressing high levels of inflammatory factors and chemokines. 6, 7 Thus, the suppression of the MF characteristics of CAFs can be a novel treatment strategy for a chemotherapeutic-resistant lung cancer with myofibroblastic CAFs.
Plasminogen activator inhibitor-1 (PAI-1), which is produced by endothelial cells of blood vessels, inflammatory cells and fibroblasts, is a glycoprotein with 47-kDa molecular size and inhibits the activation of plasminogen activator. 8 PAI-1 was reported to promote pulmonary fibrosis by blocking fibrinolysis in the lung parenchyma, 9 and also its association with TGF-β induces the differentiation of fibroblasts into MFs. 10 PAI-1 has been also reported to be involved in resistance to chemotherapy and tumourigenesis in various types of cancers. [11] [12] [13] In vivo studies revealed the significance of PAI-1 in regulating tumour angiogenesis. [14] [15] [16] Furthermore, several in vitro studies have shown that PAI-1 has a direct pro-proliferative 17 and
anti-apoptotic 18 effect on the cancer cells.
From these observations, we suggested that the inhibition of PAI-1 could increase the efficacy of chemotherapy on lung cancer by suppressing the MF characteristics of CAFs. In this study, we aimed to elucidate this hypothesis using PAI-1 inhibitor.
| MATERIAL S AND ME THODS

| Materials
Murine Lewis lung carcinoma cells (LLC) and mouse lung fibroblasts Cell Bank (Tokyo, Japan). Original human fibroblasts were obtained from carcinomatous pleural effusions in patients with lung adenocarcinoma. We called these fibroblasts CAF, because these fibroblasts existed with cancer cells in the pleural effusion, similar to fibroblasts in the tumour stroma. Briefly, the method to purify these fibroblasts was as follows. The cells in the pleural effusion were collected by centrifugation at 1500 r.p.m for 3 minutes.
After that, the cells were resuspended with 20 mL of Roswell Park 
| Reagents
SK-216 ( Figure S1 ) was chemically synthesized and supplied by Shizuoka Coffein Co., Ltd. (Shizuoka, Japan). The IC 50 for SK-216 was determined to be 44 μmol/L as reported in international patent WO04/010996. Afatinib and cisplatin were purchased from Wako Junyaku Kogyo Co. (Osaka, Japan). 
| Quantitative real-time PCR
| Quantification of PAI-1 and TGF-β protein
Total PAI-1 or TGF-β secreted into serum-free culture medium for 36 hours and in the serum were measured using an ELISA kit (R&D systems, Minneapolis, MN) following the manufacturer's instructions.
| Immunohistochemical staining
Human tumour sections were incubated with a PAI-1 (Santa Cruz, CA, USA), α-SMA (Abcam, Cambridge, UK) rabbit poly- Immunofluorescence staining for the detection of α-SMA was performed following our previous report. 10 To detect α-SMA, α-SMA antibodies (R&D systems) were used. Nuclei were stained with 4', 6-diamidino-2-phenylindole (Vector Laboratories). All images were captured using a microscope at a magnification of 40 or 200× (model BZ-9000; Keyence, Osaka, Japan). The stromal area, excluding cancer cells, was manually identified and calculated using Dynamic cell count software BZ-HIC (Keyence). Afterwards, the PAI-1 or α-SMA positive area was measured using the software. Finally, the percentage of PAI-1 or α-SMA positive area in the stromal area was determined.
| iTRAQ proteomics
A commercial iTRAQ analysis system (Filgen, Nagoya, Japan) was used with mass spectrometry. Briefly, the total protein from whole cells was purified, and 100 μg of protein samples was reduced and alkylated prior to trypsin digestion, and the resulting peptides were lyophilized and reconstituted before labelling with 
| Phospho-mitogen-activated protein kinase (MAPK) array
The total protein from whole cells were purified. Cell lysates were incubated with the Human Phospho-MAPK Array Kit (R&D Systems) according to the manufacturer's instructions. Phospho-MAPK Array data was visualized using a chemiluminescence detection system (WSE-6100;
ATTO, Tokyo, Japan) and measured using ImageSaver6 (ATTO).
| Apoptosis and cell cycle assay
Apoptosis was investigated using ApoLive-Glo Multiplex Assay 
| Proliferation assay
The proliferation of cells was analysed using the cell counting kit-8 (DOJINDO, Kumamoto, Japan) following the manufacturer's instructions.
| In vitro analysis of efficacy of chemotherapy drugs on cancer cells co-cultured with fibroblasts
As described in the Cell culture and treatment section, after 36 hours, the fibroblasts were treated with SK-216 and TGF-β1, the insert well with the fibroblasts was transferred into a new 24-well plate. Thereafter, A549, PC-9 or LLC cells were seeded at a density of 4 × 10 4 cells/well in the 24-well plate, and co-culture of cancer cells with fibroblast was started. Figure S2 shows the scheme of this in vitro model. After 36 hours, cisplatin (10 μmol/L) or afatinib
(1 μmol/L) was added to the medium. The proliferation of cancer cells was determined after 36 hours.
| Statistical analysis
Statistical analyses were undertaken using SPSS 17 (SPSS Japan was not significantly correlated with that in the serum ( Figure 1L ).
| PAI-1 was associated with the maintenance of MF characteristics of fibroblasts
First, to confirm that the cells with spindle shape obtained from the carcinomatous pleural effusion were fibroblasts, we investigated the mRNA expression of α-SMA and FAP by qPCR. qPCR revealed that the cells expressed these mRNA similar to MRC-5 cells (Figure 2A, B) . Therefore, we confirmed these cells were CAFs.
Next, to examine whether PAI-1 had an association with maintaining the MF characteristics of CAFs, we investigated whether PAI-1 inhibition limited the α-SMA expression of CAFs. As Figure 2C shown to be significantly reduced by using PAI-1-siRNA compared with NC-siRNA ( Figure S2C ). In addition, the α-SMA expression of CAFs was significantly suppressed by the siRNA ( Figure S2D ). In the experiments using MRC-5 cells, similar results were observed ( Figure S2E -G). Table S1 . 
| Analysis of the underlying the association between PAI-1 and MF phenotype of CAFs
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| PAI-1 maintained the MF characteristics of CAFs by inhibiting apoptosis
The iTRAQ analysis revealed that the expression level of many apoptosis-related proteins was elevated in the CAFs by PAI-1 inhibition. Thus, we investigated whether PAI-1 maintained the MF characteristics by inhibiting apoptosis of CAFs. We showed that PAI-1 inhibition in CAFs by treatment with SK-216 significantly decreased cell viability ( Figure 3B ) and increased the caspase activity and the amount of single strand DNA ( Figure 3C and D) . In addition, cell cycle analysis revealed the proportion of S phase cells decreased and G0/G1 phase cells significantly increased in the SK-216-treated groups than in the control. However, the degree of phosphorylation of MAPK protein was not different between CAFs treated with SK-216 and untreated control ( Figure   S4A and B). 
| Inhibition of PAI-1 increased the effect of chemotherapy on lung cancer cells co-cultured with fibroblasts through suppressing the MF characteristics of fibroblasts
We investigated whether the suppression of the MF characteristics of CAFs by PAI-1 inhibition increased the effect of chemotherapy ( Figure S2 ). As shown in the Figure 4A qPCR showed the expression of mesenchymal markers, α-SMA and fibronectin was significantly higher in control than that in SK-216 treated group. On the other hand, the expression of the epithelial marker, e-cadherin was not changed ( Figure 4F ).
| The level of PAI-1 expression correlated with α-SMA expression of CAFs and was associated with lung cancer progression
In this study, we investigated the association between PAI-1 and chemotherapy resistance. Finally, to investigate whether PAI-1 F I G U R E 3 Plasminogen activator inhibitor-1 (PAI-1) maintained MF characteristics of cancer-associated fibroblasts (CAFs) through inhibiting apoptosis. CAFs were cultured with or without SK-216 (500 μmol/L) in the medium. After 36 hours, the cell lysates were subjected to quantitative proteomic analysis. We showed that PAI-1 expression was significantly higher in the patients with T 3/4, stage 2/3 than in the patients with T 1/2, stage 1 respectively (Table 2) . 
| D ISCUSS I ON
In this study, we showed that the level of PAI-1 was correlated with the proportion of MF characteristics of CAFs in lung adenocarcinoma.
Further, we revealed that PAI-1 was associated with maintaining the MF characteristics of fibroblasts via inhibition of apoptosis. Furthermore, the inhibition of PAI-1 suppressed the MF characteristics of fibroblasts and this suppression increased the effect of chemotherapy on lung cancer cells. Finally, we showed that the level of PAI-1 in the lung adenocarcinoma was also associated with the tumour progression.
A large number of studies showed that cancer stromal cells, such as inflammatory cells, endothelial cells and fibroblasts, induced resistance to chemotherapy in lung cancer. 25 In the stromal cells, fibroblasts have been reported to be a main player in this phenomenon. 4, 26 In the present study, we revealed that PAI-1 inhibition limited the chemotherapy resistance through suppressing the MF characteristics of CAFs. In addition, we showed that the level of PAI-1 produced by CAFs was higher than that produced after suppression of the MF characteristics of CAFs by PAI-1 inhibition. This result indicates that there could be a positive feedback loop between PAI-1 and the MF characteristics of CAFs ( Figure S5 ). Thus, PAI-1 could be a reasonable therapeutic target to inhibit resistance to chemotherapy in the lung cancer with CAFs.
In this study, PAI-1 maintained the MF characteristics of CAFs through inhibiting apoptosis. PAI-1 is reported to be involved in various cancer cell properties such as migration, invasion and proliferation. 8, [27] [28] [29] Several studies showed PAI-1 was involved in these processes through association with apoptosis, 18 PI3k/Akt, MAPK 17, 30 and TGF-β signalling including EMT. 10, 24 In this study, when CAFs were treated with a PAI-1 inhibitor, the greater number of proteins related to apoptosis were up-regulated as compared to that of MAPK From these observations, we conclude that apoptosis is an important mechanism by which PAI-1 maintains the MF characteristics of CAFs.
Several reports showed that CAFs promote tumour progression and resistance to chemotherapy by secreting various growth factors and inflammatory chemokines. 4, 5 In this study, the level of PAI-1 and TGF-β secreted after suppression of the MF characteristics of CAFs by PAI-1 inhibition was significantly lower than that from CAFs without PAI-1 inhibition. Thus, we considered the PAI-1 and TGF-β secreted by CAFs could be associated with resistance to chemotherapy in cancer cells in this study. PAI-1 and TGF-β were reported to be associated with EMT of cancer cells in the absence of CAFs.
10
In this study, the expression of mesenchymal genes was elevated in the cancer cells co-cultured with CAFs compared with CAFs treated with PAI-1 inhibitor. This result suggested that EMT induced by PAI-1 and TGF-β in cancer cells was associated with decreasing the effect of chemotherapy in this study, as previously described. 10, 17, 18 Previous studies revealed that PAI-1 produced by cancer cells was associated with cancer progression and prognosis in various malignancies. [32] [33] [34] On the other hand, we previously reported that host, but not tumour, PAI-1 is important in lung cancer progression in vitro and in vivo. 15 In this present study, we showed that the high level of host PAI-1 expression in the tumour stroma was associated with tumour size and the TNM stage using immunohistochemical 
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The correlation between PAI-1, α-SMA expression and patient characteristics analysis of lung cancer tissue. Our findings suggest that PAI-1 could be a suitable treatment target for progressive tumour with abundant stroma cells that produce PAI-1.
Our data suggest that PAI-1 may influence the tumour progression and effectiveness of chemotherapy through its association with the MF characteristics of CAFs. Hence, PAI-1 might become a promising target for anti-tumour therapy in the lung cancer with CAFs. 
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